< Suzie Chen EOHSI Directory | EOHSI

Suzie Chen » EOHSI Directory

A B C D E F G H I J K L M N O P R S T U W Y Z

Suzie Chen

Professor Rutgers – Ernest Mario School of PharmacyEOHSI – Toxicology
Address Lab for Cancer Research Room 213 164 Frelinghuysen Road Piscataway NJ 08854 Phone: 848-445-7243 Fax: 732-445-0687
Photo of Suzie Chen

Biographical Info

Research Areas

The main interest in my laboratory is to study the molecular mechanisms of melanoma development using a line of transgenic mice (TG-3) generated in my lab several years ago. From mapping studies, we have determined that about 70 kb of host sequences have been deleted by the insertion of the transgene. The host DNA had been deleted from a region of mouse chromosome 10 which is syntenic to the long arm of human chromosome 6. This region of human chromosome 6 has been shown to be highly rearranged in a large number of human nonfamilial malignant melanomas. A combination of techniques were used to identify intron 3 of metabotropic glutamate receptor 1 (Grm1) as the gene disrupted by the insertion of the transgene. The metabotropic glutamate receptors (mGluRs) belong to a family of seven transmembrane domain, G-protein coupled receptors (GPCRs). Expression of mGluRs is usually restricted to neuronal cells, but the signaling pathways activated by these receptors are widely distributed in both neural and non-neural cells. Mice with null mutations in Grm1 display reductions in hippocampal long term potentiation, and abnormalities of motor coordination and associative learning. In the TG-3 line, we showed that Grm1 is expressed only in ear tumors, but not normal ear as demonstrated by semi-quantitative RT-PCR, Western immunoblots, immunofluorescence and immunohistochemistry. Co-localization of Grm1 and the melanocyte-marker Tyrp-1 was detected only in tumors and not in the normal counterparts. Based on these results, a new transgenic line was generated with targeted Grm1 expression to melanocytes, by using Grm1 cDNA under the melanocyte-specific Dct (dopachrome tautomerase) promoter. Founder of Dct-Grm1 exhibited melanotic tumors on the tail at 7.5 months of age. High levels of Grm1 expression were observed in tail tumors but not in normal tail. Histopathological analysis showed these tumors to be very similar to those of TG-3. These results provide the compelling evidence suggesting the improtance of Grm1 signaling in melanocytic neoplasia.

Together with Dr. J. Goydos at CINJ, we begin to explore the potential role of the aberrant expression of Grm1 in human melanoma development and progression. Our data on human melanoma biopsy samples (7/19) showed expression of Grm1. Grm1 expression was not detected in two benign nevi and one normal skin samples. Similar analyses were also done with 18 human melanoma cell lines, 12/18 of these cell lines showed Grm1 expression, these results were confirmed by immunofluorescence. Co-localization of Grm1 and Tyrp1 (a melanocyte-specific marker) was detected only in lines that also showed Grm1 expression.

Research Highlights

  • Melanoma research
  • Melanoma research from bench to the clinic.

Scholarly Activities

  • 2014 – present Council member of PanAmerican Society for Pigment Cell Research
  • 2011 – present VA Oncology Study Section
  • 2004 – present Member, NCI Special Emphasis Panel
  • 2000 – present Planning and Review Committee for the Annual Retreat on Cancer Research
  • 2004-2010 National Institute of Health Grant
  • 2007-2012 National Institute of Health Grant
  • 2009-2011 State of New Jersey Commission on Cancer Research Grant

Recent Publications

  1. Marciel, MP, Khadka, VS, Deng, Y, Kilicaslan, P, Pham, A, Bertino, P, Lee, K, Chen, S, Glibetic, N, Hoffmann, FW et al.. Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis. Oncotarget. 2018;9 (17):13407-13422. doi: 10.18632/oncotarget.24388. PubMed PMID:29568366 PubMed Central PMC5862587
  2. Lopez-Tapia, F, Brotherton-Pleiss, C, Yue, P, Murakami, H, Costa Araujo, AC, Reis Dos Santos, B, Ichinotsubo, E, Rabkin, A, Shah, R, Lantz, M et al.. Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors. ACS Med Chem Lett. 2018;9 (3):250-255. doi: 10.1021/acsmedchemlett.7b00544. PubMed PMID:29541369 PubMed Central PMC5846032
  3. Chen, HC, Sierra, J, Yu, LJ, Cerchio, R Jr, Wall, BA, Goydos, J, Chen, S. Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo. Oncotarget. 2018;9 (5):5861-5875. doi: 10.18632/oncotarget.23637. PubMed PMID:29464040 PubMed Central PMC5814180
  4. Mehnert, JM, Silk, AW, Lee, JH, Dudek, L, Jeong, BS, Li, J, Schenkel, JM, Sadimin, E, Kane, M, Lin, H et al.. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell Melanoma Res. 2018;31 (4):534-540. doi: 10.1111/pcmr.12694. PubMed PMID:29453787 PubMed Central PMC6013351
  5. Isola, AL, Eddy, K, Zembrzuski, K, Goydos, JS, Chen, S. Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness. Oncotarget. 2018;9 (1):1187-1199. doi: 10.18632/oncotarget.23455. PubMed PMID:29416686 PubMed Central PMC5787429
  6. Chaker, M, Minden, A, Chen, S, Weiss, RH, Chini, EN, Mahipal, A, Azmi, AS. Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin. Ther. Targets. 2018;22 (1):9-17. doi: 10.1080/14728222.2018.1413091. PubMed PMID:29207896
  7. Chen, S. Editorial: GPCRs and Cancer. Front Genet. 2017;8 :162. doi: 10.3389/fgene.2017.00162. PubMed PMID:29163632 PubMed Central PMC5671489
Search PubMed
Categories: Faculty, Toxicology

Join Our Email List!

Please subscribe to our mailing list if you wish to receive EOHSI Seminar and Events announcements.

If you are a subscriber and your e-mail address has changed or you are not receiving our e-mail alerts, please send a new request to update your contact information.





Your Name (required)

Your Email (required)